A5048800582- Breast Cancer Treatment Studies
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Breast Implant and Reconstruction
- Inflammatory Biomarkers in Disease Prognosis
- Breast Lesions and Carcinomas
- HER2/EGFR in Cancer Research
- Head and Neck Cancer Studies
- Cancer Risks and Factors
- Cancer Diagnosis and Treatment
- Microbial Metabolites in Food Biotechnology
- Women's cancer prevention and management
- Genomics and Rare Diseases
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Male Breast Health Studies
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Multiple and Secondary Primary Cancers
- Esophageal Cancer Research and Treatment
- CRISPR and Genetic Engineering
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Lipids, and Metabolism
Hospital Universitario Austral
2014-2024
Fundación para la Investigación, Docencia y Prevención del Cáncer
2023
Hospital Británico de Buenos Aires
2002
BRCA1/2 mutations in Latin America are scarcely documented and serious need of knowledge about the spectrum BRCA pathogenic variants, information which may alter clinical practice subsequently improve patient outcome. In addition, search for data on testing policies different regions constitutes a fundamental strength present study, analyzes gene sequences large rearrangements 940 probands with familial and/or personal history breast/ovary cancer (BOC). non-mutated DNA samples, Multiplex...
We present a physician survey of the impact 21-gene Breast Recurrence Score test results on treatment decisions in clinical practice Latin America.This prospective enrolled consecutive patients at 14 sites Argentina, Colombia, Mexico, and Peru who had routine testing. Physician surveys captured patient tumor characteristics before after results. The spanned period Trial Assigning Individualized Options for Treatment (TAILORx) reported (June 2018). Overall net percent change adjuvant...
In conservative early stage breast cancer surgery, the sample's margins are directly related to relapse, and positive or close indicate need for additional surgery. Since range of residual disease in secondary surgeries pathological factors highly variable, we intended evaluate number due compromised identify percentage it.We retrospectively analyzed clinical records 659 tumorectomy needle localization surgery patients with carcinoma at Hospital Universitario Austral Buenos Aires, Argentina,...
Currently, therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is based on the combination of trastuzumab and pertuzumab plus chemotherapy in a neoadjuvant regimen. The INMUNOHER study aimed to detect immunological markers peripheral blood their association with treatment response. Sixty-two HER2+ BC patients were recruited. Pre-treatment samples obtained before start treatment, while post-treatment after completing surgery analyzed by flow...
Breast cancer is a highly heterogeneous disease with large differences in the risk of recurrence. An elevated neutrophil-to-lymphocyte ratio (NLR) correlated poor prognosis variety tumors, and although it still controversial breast cancer, there are multiple studies, including meta-analysis, suggesting this. The purpose this study was to analyze prognostic value preoperative NLR an Argentine population patients nonmetastatic not exposed neoadjuvant treatment.Retrospective multicenter cohort...
Background:The number of risk-reducing mastectomies (RRM) has increased over the past years as genetic testing become more readily available. Objective:The aim this study was to analyze experience a University Hospital in Argentina Material and methods: The analysis included healthy patients undergoing simultaneous bilateral RRM those with history breast cancer who underwent contralateral RRM.Patients mastec¬tomies performed treatment were not considered, but included.Results: Seventy 49...
Trastuzumab (TRZ) fue el primer anticuerpo monoclonal (AcM) IgG humanizado aprobado para tratamiento del cáncer de mama (CM). Desde su aprobación en 1998, se estima que ha administrado a más 2,5 millones mujeres todo mundo y encuentra la lista medicamentos esenciales OMS. TRZ revolucionado terapia CM HER2+. Tanto los mecanismos no inmunológicos como inmunomediados explican actividad clínica TRZ.
 La asociación entre polimorfismo FcƴRIIIa eficacia terapéutica AcMs comprobado varios...
Antecedentes: dada la mayor disponibilidad de estudios genéticos, en los últimos años se incrementaron significativamente las mastectomías reducción riesgo (MRR).Objetivo: analizar experiencia institucional MRR.Material y métodos: tuvieron cuenta pacientes sanas sometidas a MRR bilateral simultánea también con antecedentes cáncer mama que luego fueron contralateral.No tenidas realizadas como tratamiento actual un cáncer, pero sí mastectomía contralateral.Resultados: realizaron 70 49 cumplían...
Introduction: At present, more than half of patients diagnosed with early-stage breast cancer (BC) and express hormonal receptors will receive some adjuvant chemotherapy scheme, but only a few them would benefit in terms survival. Genomic platforms allow better understanding the heterogeneity different types receptor-positive HER2-negative BC. They have proven their validity as tools to identify those who obtain clear indication treatment. The aim this study is analyze use genomic platform,...